Fouad Aoun, Carlos Artigas, Patrick Flamen and Roland van Velthoven
Prostate-specific membrane antigen (PSMA) is a membrane glycoprotein that is a well-characterized and clinically validated marker of prostate cancer (PCa)
Gallium 68 (68Ga)–labeled PSMA PET/CT uses the affinity of the 68Ga-labeled PSMA ligand to PSMA expressing cells. Promising results were reported for an accurate staging in patients presenting with biochemical recurrence (BCR) after primary treatment even at low PSA levels. We present the case of a 56 years old patient presenting with a BCR (PSA=21 ng/ml) several years after external radiation beam therapy. Abdominopelvic CT scan and bone scan were negative. A suspicious lesion on PSMA-ligand PET imaging was detected in the prostate with no evidence of regional or distant hypermetabolic lesions
English 
Spanish 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi